Overall, the lifetime prevalence for all types of urticaria is 8.8%, but Chronic urticaria (CU) only develops in 30–45% of these individuals. Traditionally, chronic urticaria/angioedema has been defined as weal’s, angioedema or both with daily or almost daily symptoms lasting for more than 6 weeks. The current article describes the British Society for Allergy and Clinical Immunology (BSACI) guidelines, 2015 for the management of patients with chronic urticaria/angioedema. The guideline states the prevalence, clinical classification, pathophysiology, investigations, diagnosis and management regimen of the patients with chronic urticaria/angioedema.
The guideline further stated that there are important differences in etiology and management in children compared to adults. The guideline also discussed pharmacological therapy of chronic urticaria/angioedema. Other important recommendations…
